Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.
Separately, Maxim Group set a $8.00 target price on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Wednesday, April 19th.
Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up 0.68% on Friday, hitting $4.45. The stock had a trading volume of 78,723 shares. The stock’s market cap is $83.37 million. Brainstorm Cell Therapeutics has a 12 month low of $2.06 and a 12 month high of $5.10. The firm has a 50 day moving average of $4.26 and a 200 day moving average of $3.84.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.20. On average, equities analysts forecast that Brainstorm Cell Therapeutics will post ($0.79) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Stock Rating Lowered by ValuEngine” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/19/brainstorm-cell-therapeutics-inc-nasdaqbcli-stock-rating-lowered-by-valuengine.html.
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. KCG Holdings Inc. raised its position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 4.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 41,537 shares of the biotechnology company’s stock after buying an additional 1,820 shares during the period. KCG Holdings Inc. owned about 0.22% of Brainstorm Cell Therapeutics worth $177,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.02% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
